Table 2.

Meta-analysis of the association between the IL1B–511 C>T (rs16944) polymorphism and the risk of hematological malignancies (allelic and genotypic comparisons; and stratified analysis).

Variable	Comparison		M versus m		m versus M
rs16944	(n)	Case/Control	OR (95% CI)	p-value	OR (95% CI)	p-value
Overall	12	2,892/3,716	1.06 (0.93, 1.22)	.37	0.94 (0.82, 1.08)	.37
MM	2	429/510	1.28 (0.81, 2.02)	.29	0.78 (0.49, 1.23)	.29
HL	2	495/1,043	1.02 (0.84, 1.24)	.85	0.98 (0.80, 1.20)	.85
NHL	2	791/823	1.00 (0.63, 1.61)	.98	1.00 (0.62, 1.60)	.98
European	4	859/930	0.86 (0.57, 1.30)	.48	1.16 (0.77, 1.74)	.48
Asian	6	1,824/1,766	1.09 (0.99, 1.20)	.09	0.92 (0.83, 1.01)	.09
HWE yes	11	2,741/3,551	1.05 (0.91, 1.20)	.54	0.96 (0.83, 1.10)	.54
Variable	Comparison		MM versus mm		mm versus MM
rs16944	(n)	Case/Control	OR (95% CI)	p-value	OR (95% CI)	p-value
Overall	12	2,892/3,716	1.13 (0.85, 1.50)	.40	0.89 (0.67, 1.18)	.40
MM	2	429/510	1.31 (0.72, 2.36)	.37	0.76 (0.42, 1.38)	.37
HL	2	495/1,043	0.84 (0.40, 1.77)	.65	1.19 (0.56, 2.50)	.65
NHL	2	791/823	1.23 (0.23, 6.49)	.80	0.81 (0.15, 4.27)	.80
European	4	859/930	0.67 (0.34, 1.32)	.24	1.50 (0.76, 2.94)	.24
Asian	6	1,824/1,766	1.15 (0.96, 1.38)	.13	0.87 (0.72, 1.04)	.13
HWE yes	11	2,741/3,551	1.05 (0.80, 1.38)	.70	0.95 (0.72, 1.25)	.70
Variable	Comparison		MM versus mm/Mm		Mm versus mm/MM
rs16944	(n)	Case/Control	OR (95% CI)	p-value	OR (95% CI)	p-value
Overall	12	2,892/3,716	1.31 (0.94, 1.84)	.11	1.15 (0.81, 1.64)	.44
MM	2	429/510	1.14 (0.84, 1.55)	.41	1.43 (0.52, 3.95)	.49
HL	2	495/1,043	2.23 (0.54, 9.16)	.27	3.23 (0.14, 73.44)	.46
NHL	2	791/823	1.55 (0.41, 5.87)	.52	0.86 (0.61, 1.22)	.39
European	4	859/930	0.89 (0.70, 1.14)	.37	0.97 (0.57, 1.64)	.90
Asian	6	1,824/1,766	1.54 (0.93, 2.56)	.10	1.35 (0.73, 2.51)	.34
HWE yes	11	2,741/3,551	1.23 (0.87, 1.73)	.23	1.21 (0.83, 1.76)	.32

M, mutant allele; m, wild-type allele; OR, odds ratio; CI, confidence interval.

MM:multiple myeloma, HL: Hodgkin’s lymphoma, NHL: non-Hodgkin’s lymphoma.

HWE: Hardy–Weinberg equilibrium.